BRPI0511066A - compostos tipo leptomicina, composição farmacêutica compreendendo os mesmos e usos - Google Patents

compostos tipo leptomicina, composição farmacêutica compreendendo os mesmos e usos

Info

Publication number
BRPI0511066A
BRPI0511066A BRPI0511066-1A BRPI0511066A BRPI0511066A BR PI0511066 A BRPI0511066 A BR PI0511066A BR PI0511066 A BRPI0511066 A BR PI0511066A BR PI0511066 A BRPI0511066 A BR PI0511066A
Authority
BR
Brazil
Prior art keywords
leptomycin
compounds
pharmaceutical compositions
type compounds
report
Prior art date
Application number
BRPI0511066-1A
Other languages
English (en)
Inventor
Steven D Dong
Daniel V Santi
David C Myles
Brian Hearn
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35449817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0511066(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of BRPI0511066A publication Critical patent/BRPI0511066A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)

Abstract

COMPOSTOS TIPO LEPTOMICINA, COMPOSIçãO FARMACêUTICA COMPREENDENDO OS MESMOS E USOS Compostos tipo leptomicina de acordo com a fórmula I em que R¬ 0¬,¬ R¬, R¬ 2¬, R¬ 10¬ , R¬ 11, R¬ 12¬, R¬ 13¬, R¬ 14¬, e m são como definidos neste relatório, apresentam atividade antitumoral.
BRPI0511066-1A 2004-06-03 2005-06-03 compostos tipo leptomicina, composição farmacêutica compreendendo os mesmos e usos BRPI0511066A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57725304P 2004-06-03 2004-06-03
US60998104P 2004-09-14 2004-09-14
US11/142,482 US7446196B2 (en) 2004-06-03 2005-06-01 Leptomycin compounds
PCT/US2005/019591 WO2005117894A1 (en) 2004-06-03 2005-06-03 Leptomycin compounds

Publications (1)

Publication Number Publication Date
BRPI0511066A true BRPI0511066A (pt) 2007-12-26

Family

ID=35449817

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511066-1A BRPI0511066A (pt) 2004-06-03 2005-06-03 compostos tipo leptomicina, composição farmacêutica compreendendo os mesmos e usos

Country Status (10)

Country Link
US (2) US7446196B2 (pt)
EP (1) EP1765354A4 (pt)
JP (1) JP2008501710A (pt)
KR (1) KR20070047276A (pt)
AU (1) AU2005249555A1 (pt)
BR (1) BRPI0511066A (pt)
CA (1) CA2568341A1 (pt)
IL (1) IL179772A0 (pt)
MX (1) MXPA06014045A (pt)
WO (1) WO2005117894A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7446196B2 (en) * 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
US20060099235A1 (en) * 2004-11-11 2006-05-11 Medtronic Vascular, Inc. Medical devices and compositions useful for treating or inhibiting restenosis
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
BRPI0713031B8 (pt) * 2006-06-16 2021-05-25 Pharma Mar Sa composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
EP2124927A2 (en) * 2007-02-26 2009-12-02 Kosan Biosciences Incorporated Carbamate compounds
KR101541436B1 (ko) * 2007-12-20 2015-08-03 파르마 마르 에스.에이. 항암 화합물
AU2012216670B2 (en) * 2007-12-20 2013-11-21 Pharma Mar S.A. Antitumoral compounds
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
EP2431364A1 (en) 2010-09-16 2012-03-21 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Nuclear export inhibitors
KR102479693B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 조합물
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
EP3665161B1 (en) 2017-08-09 2023-09-27 Helmholtz-Zentrum für Infektionsforschung GmbH New targeted cytotoxic ratjadone derivatives and conjugates thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4792522A (en) 1983-12-12 1988-12-20 Bristol-Myers Company Rigolettone antitumor complex
US4771070A (en) 1984-08-21 1988-09-13 Warner-Lambert Company CL-1957A antibiotic compound
US4725621A (en) 1986-03-03 1988-02-16 Warner-Lambert Company CL-1957E antibiotic compound and its production
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6830663B2 (en) * 1999-01-26 2004-12-14 Symyx Technologies, Inc. Method for creating radial profiles on a substrate
WO2001014406A1 (fr) * 1999-08-23 2001-03-01 Chugai Seiyaku Kabushiki Kaisha Agents anti-androgènes
US7238525B2 (en) 2000-06-30 2007-07-03 The Regents Of The University Of California Strategy for leukemia therapy
US7163669B2 (en) 2002-06-19 2007-01-16 J.M. Huber Corporation Cosmetic compositions comprising calcium silicates
US7446196B2 (en) * 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds

Also Published As

Publication number Publication date
US7655808B2 (en) 2010-02-02
US20090042837A1 (en) 2009-02-12
US20050272727A1 (en) 2005-12-08
EP1765354A4 (en) 2009-04-15
JP2008501710A (ja) 2008-01-24
WO2005117894A1 (en) 2005-12-15
IL179772A0 (en) 2007-05-15
AU2005249555A1 (en) 2005-12-15
EP1765354A1 (en) 2007-03-28
CA2568341A1 (en) 2005-12-15
US7446196B2 (en) 2008-11-04
KR20070047276A (ko) 2007-05-04
MXPA06014045A (es) 2007-02-28

Similar Documents

Publication Publication Date Title
BRPI0511066A (pt) compostos tipo leptomicina, composição farmacêutica compreendendo os mesmos e usos
BRPI0518752A2 (pt) 1-alquinil-2-arilàxi-alquil-amidas e uso do mesmo como fungicidas
BRPI0409591A (pt) composições com múltiplas fases lìquidas visualmente distintas
JO2770B1 (en) Organic compounds
UA94417C2 (ru) Замещенные 7-азаиндазолы, композиция, которая их содержит, и применение
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BRPI0518758A2 (pt) compostos de acetamida como fungicidas
BRPI0514665A2 (pt) compostos com atividade antibacteriana, composições farmacêuticas e uso dos mesmos
UA91854C2 (ru) Фунгицидная комбинация действующих веществ
TW200732323A (en) Organic compounds
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
TW200716584A (en) Dihydrobenzofuran derivatives and uses thereof
BRPI0810064B8 (pt) compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos
UY29486A1 (es) Compuestos utiles en terapia
MX2009004132A (es) Composiciones para contrarrestar el mal olor.
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
UY28917A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico
BRPI0605926A2 (pt) ciclopentanos substituìdos ou ciclopentanonas como agentes terapêuticos
TW200738627A (en) Trialkylsilyl-indoles
BRPI0411001A (pt) produtos aril-heteroaromáticos, composições que os contêm e utilização
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
BRPI0407088A (pt) Produtos n-aril-heteroaromáticos, composições contendo os mesmos e seu uso
CR10371A (es) Compuestos heterociclicos apropiados para tratar trastornos que responden a la moduilacion del receptor de serotonina 5ht6
MX2009000768A (es) Lactamas macrociclicas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.